VANCOUVER, Jan. 22, 2020 /CNW/ – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) announces that the final toxicology test, a Human Repeated Insult Patch Test (“HRIPT”), has successfully been completed. Sirona is now in preparation for the increased dose (0.4%) clinical study for its skin lightening compound TFC-1067.

The HRIPT study was coordinated by Eurofins Dermscan in Poland (www.eurofins.com) and was executed by Eurofins EVIC Product Testing Romania under the direction of a clinical dermatologist. During the study, the formulation containing 0.4% TFC-1067 was applied to 103 participants repeatedly, 9 times, to the same site over a period of three consecutive weeks to induce a possible allergy. After a minimal 2-week rest period, another single application of the product was applied, under patch, to the induction site and to a new site for a defined time in order to reveal a possible induced allergy.

The cream containing 0.4% TFC-1067 showed 100% safety in all subjects. No negative reactions were observed during the study period.

The written report of the study concluded the following: “Based on these results, the product has a very good skin compatibility and does not show a sensitizing effect.”

“Again, we’ve received excellent results with our skin lightening compound TFC-1067. This compound is very safe at our current dose and anticipated to be more effective for creating a brighter, more even skin tone,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We are now working with Eurofins Dermscan to establish the protocol for the clinical study which we expect to start within the next few months.”

The clinical trial is anticipated to be a value-add for the compound. Current licenses and ongoing product development by partners for TFC-1067 will not be delayed by the studies.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.

For more information, please visit www.sironabiochem.com.